
    
      Patients will be screened daily. Patients who meet eligibility criteria will be approached
      for participation. Patients interested in participating will proceed through informed
      consent. Once informed consent is obtained, an initial questionnaire will be administered, a
      blood draw will be performed to assess for baseline Vitamin D/O3FA concentration and immune
      profile. Then patients will be randomized into one of 4 treatment arms in 1:1:1:1 allocation.
      Patients will receive study drug for 6 weeks following burn injury. Adverse event monitoring
      will occur daily while inpatient and weekly once discharged from the hospital through 6
      weeks. Patient compliance with the study drug will be assessed via patient-reported reported
      missing doses, pill counts at the end of the study, and a 6-week blood draw in which Vitamin
      D/O3FA levels and immune profile will be assessed. Patient-reported outcomes will be
      collected via follow-up survey at 6 weeks, 3 months, 6 months, and 1 year following burn
      injury.s, and 1 year following burn injury.
    
  